Innovent Biologics Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Innovent Biologics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C2814
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:32
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Innovent Biologics Inc (Innovent Biologics) is a biopharmaceutical company that discovers, develops and manufactures monoclonal antibodies. The company offers monoclonal antibodies such as IBI301, IBI302 and IBI303, among others. Its products are used for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, crohn’s disease, and other autoimmune diseases. Innovent Biologics development platform provides pilot process development and preclinical and clinical research stage that shortens the development cycle of new drugs. The company operates in fields of oncology, autoimmune disease and ophthalmology with application to different indications. It markets its products across China. Innovent Biologics is headquartered in Suzhou, China.

Innovent Biologics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Innovent Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Innovent Biologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Innovent Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Innovent Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Innovent Biologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Innovent Biologics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Innovent Biologics Raises USD150 Million in Series E Venture Financing 11
Innovent Biologics May Raise Funds through Venture Financing 13
Innovent Biologics Raises USD260 Million in Series D Financing 14
Innovent Biologics Raises USD100 Million in Series C Venture Financing 16
Innovent Biologics Raises US$25 Million In Series B Financing 17
Innovent Biologics Raises US$5 Million In Series A Venture Financing Round 18
Partnerships 19
Hanmi Pharma Enters into Co-Development Agreement with Innovent Biologics 19
EpimAb Biotherapeutics Enters into Co-Development Agreement with Innovent Biologics 20
Eli Lilly Expands Agreement with Innovent Biologics 21
Adimab Expands Agreement with Innovent Biologics 22
Aragen Bioscience Enters Into Co-Development Agreement With Innovent Biologics For Biotherapeutic Products 23
Licensing Agreements 24
Harbour BioMed Enters into Licensing Agreement with Innovent Biologics 24
Innovent Biologics Enters into Licensing Agreement with Chinese Academy and Shanghai Institute of Organic 25
Equity Offering 26
Innovent Biologics Files to Raise Funds through IPO of Shares 26
Innovent Biologics Inc – Key Competitors 27
Innovent Biologics Inc – Key Employees 28
Innovent Biologics Inc – Locations And Subsidiaries 29
Head Office 29
Recent Developments 30
Product News 30
07/25/2018: Innovent receives IND approval to initiate clinical trials in china with its aanti-RANKL Antibody IBI307 30
07/25/2018: Innovent receives IND approval to initiate clinical trials in china with its anti-OX40 Agonistic Antibody IBI101 31
Appendix 32
Methodology 32
About GlobalData 32
Contact Us 32
Disclaimer 32

List of Tables
Innovent Biologics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Innovent Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Innovent Biologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Innovent Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Innovent Biologics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Innovent Biologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Innovent Biologics Raises USD150 Million in Series E Venture Financing 11
Innovent Biologics May Raise Funds through Venture Financing 13
Innovent Biologics Raises USD260 Million in Series D Financing 14
Innovent Biologics Raises USD100 Million in Series C Venture Financing 16
Innovent Biologics Raises US$25 Million In Series B Financing 17
Innovent Biologics Raises US$5 Million In Series A Venture Financing Round 18
Hanmi Pharma Enters into Co-Development Agreement with Innovent Biologics 19
EpimAb Biotherapeutics Enters into Co-Development Agreement with Innovent Biologics 20
Eli Lilly Expands Agreement with Innovent Biologics 21
Adimab Expands Agreement with Innovent Biologics 22
Aragen Bioscience Enters Into Co-Development Agreement With Innovent Biologics For Biotherapeutic Products 23
Harbour BioMed Enters into Licensing Agreement with Innovent Biologics 24
Innovent Biologics Enters into Licensing Agreement with Chinese Academy and Shanghai Institute of Organic 25
Innovent Biologics Files to Raise Funds through IPO of Shares 26
Innovent Biologics Inc, Key Competitors 27
Innovent Biologics Inc, Key Employees 28

List of Figures
Innovent Biologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Innovent Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Innovent Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Innovent Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Innovent Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Innovent Biologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Innovent Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Innovent Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Innovent Biologics Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Nidec Corporation:企業の戦略・SWOT・財務情報
    Nidec Corporation - Strategy, SWOT and Corporate Finance Report Summary Nidec Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • GAIL (India) Limited:企業の戦略・SWOT・財務分析
    GAIL (India) Limited - Strategy, SWOT and Corporate Finance Report Summary GAIL (India) Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Acorda Therapeutics Inc (ACOR)-製薬・医療分野:企業M&A・提携分析
    Summary Acorda Therapeutics Inc (Acorda) is a biopharmaceutical company that discovers, develops, and commercializes therapies for treating patients with neurological disorders. The company’s commercial products include Ampyra (dalfampridine), a treatment to improve walking in patients with multiple …
  • Nichirei Corp (2871):企業の財務・戦略的SWOT分析
    Nichirei Corp (2871) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Ssangyong Cement Industrial Co., Ltd.:企業の戦略・SWOT・財務情報
    Ssangyong Cement Industrial Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Ssangyong Cement Industrial Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Flower Orthopedics Corp:医療機器:M&Aディール及び事業提携情報
    Summary Flower Orthopedics Corp (Flower Orthopedics) is a medical equipment provider that offers orthopedic devices. The company offers instrument kits which include K-wire kits, olive wire kits, guide wire kits, drill bit kits, lag screw kits, cannulated drill bits, trials and cannulated countersin …
  • Nexira:戦略・SWOT・企業財務分析
    Nexira - Strategy, SWOT and Corporate Finance Report Summary Nexira - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • Polpharma SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Polpharma SA (Polpharma) undertakes the research, manufacture and marketing of generic drugs, prescription drugs and over the counter medications. It provides drugs in cardiology, gastroenterology and neurology areas. The company also manufactures over the counter (OTC) medications, dietary …
  • CaixaBank SA:企業の戦略・SWOT・財務情報
    CaixaBank SA - Strategy, SWOT and Corporate Finance Report Summary CaixaBank SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Dril-Quip Inc (DRQ):企業の財務・戦略的SWOT分析
    Dril-Quip Inc (DRQ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Sevan Marine ASA (SEVAN):石油・ガス:M&Aディール及び事業提携情報
    Summary Sevan Marine ASA (Sevan Marine) is an oil and gas company that offers engineering, design, and project execution of floating units for offshore applications. The company's floating production units include Hummingbird spirit, Voyageur spirit, Piranema spirit, Goliat FPSO and Western Isles FP …
  • Islandsbanki hf.:企業の戦略・SWOT・財務分析
    Islandsbanki hf. - Strategy, SWOT and Corporate Finance Report Summary Islandsbanki hf. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Fortive Corporation:戦略・SWOT・企業財務分析
    Fortive Corporation - Strategy, SWOT and Corporate Finance Report Summary Fortive Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • UGE International Ltd (UGE):企業の財務・戦略的SWOT分析
    Summary UGE International Ltd (UGE), formerly Way Ventures Inc, is a renewable energy company that operates through wind, solar, solar-wind technologies. The company offers products such as electronics and accessories, wind turbines, solar panels, energy storage systems, mounting system, electronics …
  • Feintool International Holding AG (FTON):企業の財務・戦略的SWOT分析
    Feintool International Holding AG (FTON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Country Club Hospitality & Holidays Ltd.
    Country Club Hospitality & Holidays Ltd. - Strategy, SWOT and Corporate Finance Report Summary Country Club Hospitality & Holidays Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Roquette Freres SA:企業の戦略的SWOT分析
    Roquette Freres SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Ackermans & Van Haaren NV:戦略・SWOT・企業財務分析
    Ackermans & Van Haaren NV - Strategy, SWOT and Corporate Finance Report Summary Ackermans & Van Haaren NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Vitol Group:企業の戦略・SWOT・財務情報
    Vitol Group - Strategy, SWOT and Corporate Finance Report Summary Vitol Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • SuanFarma SA:製薬・医療:M&Aディール及び事業提携情報
    Summary SuanFarma SA (SuanFarma Group) is a drug development company that offers production, development, and marketing of raw materials and finished dosage forms. The company’s products portfolio includes amoxiciline capsules, enalapril tablets, colistin methanesulphonate, azitromicine film coated …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆